{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:10:28Z","timestamp":1761862228495},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2003,1]]},"DOI":"10.1006\/gyno.2003.6882","type":"journal-article","created":{"date-parts":[[2002,12,28]],"date-time":"2002-12-28T12:20:15Z","timestamp":1041078015000},"page":"3-8","source":"Crossref","is-referenced-by-count":27,"title":["Pilot Evaluation of High-Dose Carboplatin and Paclitaxel Followed by High-Dose Melphalan Supported by Peripheral Blood Stem Cells in Previously Untreated Advanced Ovarian Cancer: A Gynecologic Oncology Group Study"],"prefix":"10.1006","volume":"88","author":[{"given":"Russell J.","family":"Schilder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark F.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Spriggs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Shea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1006\/gyno.2003.6882_RF1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3322\/canjclin.51.1.15","article-title":"Cancer statistics, 2001","volume":"51","author":"Greenlee","year":"2001","journal-title":"CA Cancer J Clin"},{"key":"10.1006\/gyno.2003.6882_RF2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1006\/gyno.2003.6882_RF3","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","article-title":"Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin\u2013cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results","volume":"92","author":"Piccart","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1006\/gyno.2003.6882_RF4","first-page":"356a","article-title":"Randomized phase III study of cisplatin (cis)\/paclitaxel (pac) versus carboplatin (carbo\/pac) in optimal stage III epithelial ovarian cancer(OC): a Gynecologic Oncology Group trial (GOG 158)","volume":"18","author":"Ozols","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1006\/gyno.2003.6882_RF5","first-page":"356a","article-title":"Cisplatin\/paclitaxel vs carboplatin\/paclitaxel in ovarian cancer: Update of an Arbeitsgemeinschaft Gyn\u00e4ekologische Onkologie (AGO) study group trial","volume":"18","author":"Du Bois","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1006\/gyno.2003.6882_RF6","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1200\/JCO.1996.14.7.2113","article-title":"Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer","volume":"14","author":"Kaye","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2003.6882_RF7","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.1995.13.7.1589","article-title":"Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study","volume":"13","author":"McGuire","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2003.6882_RF8","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.1997.15.1.193","article-title":"Dose\u2013effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group Study","volume":"15","author":"Jakobsen","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2003.6882_RF9","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1200\/JCO.1998.16.7.2426","article-title":"Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer","volume":"16","author":"Gore","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2003.6882_RF10","first-page":"349","article-title":"Multiple cycles of high-dose chemotherapy for ovarian cancer","volume":"25","author":"Schilder","year":"1998","journal-title":"Semin Oncol"},{"key":"10.1006\/gyno.2003.6882_RF11","doi-asserted-by":"crossref","first-page":"504","DOI":"10.7326\/0003-4819-133-7-200010030-00009","article-title":"High-dose chemotherapy and autologous stem-cell transplantation for ovarian cancer: an autologous blood and marrow transplant registry report","volume":"133","author":"Stiff","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1006\/gyno.2003.6882_RF12","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1046\/j.1525-1438.2001.11(suppl.1)sup1064.x","article-title":"High dose chemotherapy in ovarian cancer","volume":"11","author":"Pujade-Lauraine","year":"2001","journal-title":"Int J Gynecol Cancer"},{"key":"10.1006\/gyno.2003.6882_RF13","series-title":"Important advances in oncology","first-page":"57","article-title":"Potential innovations in scheduling of cancer chemotherapy","author":"Norton","year":"1991"},{"key":"10.1006\/gyno.2003.6882_RF14","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1200\/JCO.1993.11.8.1583","article-title":"Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy","volume":"11","author":"Tepler","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2003.6882_RF15","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.1995.13.5.1160","article-title":"Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin\/cyclophosphamide courses","volume":"13","author":"Fennelly","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2003.6882_RF16","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1200\/JCO.1999.17.7.2198","article-title":"Phase I trial of multiple cycles of high-dose chemotherapy supported by autologous peripheral-blood stem cells","volume":"17","author":"Schilder","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2003.6882_RF17","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1200\/JCO.1998.16.5.1852","article-title":"Phase II study of \u201cdose-dense\u201d high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer","volume":"16","author":"Aghajanian","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2003.6882_RF18","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"17","author":"Calvert","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2003.6882_RF19","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-79-4-604","article-title":"Creatinine clearance bedside estimate [letter]","volume":"79","author":"Jeliffe","year":"1973","journal-title":"Ann Intern Med"},{"key":"10.1006\/gyno.2003.6882_RF20","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/S0140-6736(83)92248-1","article-title":"Prophylaxis of herpes infections after bone-marrow transplantation by oral acyclovir","volume":"2","author":"Gluckman","year":"1983","journal-title":"Lancet"},{"key":"10.1006\/gyno.2003.6882_RF21","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJM199705013361804","article-title":"High-dose chemotherapy and autologous bone marrow transplantation compared with MA-COP-B in aggressive B-cell lymphoma","volume":"336","author":"Gianni","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1006\/gyno.2003.6882_RF22","article-title":"Randomized phase III study of cisplatin (CIS)\/paclitaxel (PAC) versus carboplatin (CARBO)\/PAC in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 158)","author":"Ozols","year":"1999","journal-title":"Proc ASCO 18"},{"key":"10.1006\/gyno.2003.6882_RF23","first-page":"483","article-title":"Acute in vivo resistance high-dose therapy","volume":"4","author":"Teicher","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1006\/gyno.2003.6882_RF24","first-page":"403","article-title":"Transcriptional actors involved in cellular resistance to cisplatin","volume":"37","author":"Aghajanian","year":"1996","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1006\/gyno.2003.6882_RF25","first-page":"1508","article-title":"p53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin","volume":"61","author":"Lin","year":"2001","journal-title":"Cancer Res"},{"key":"10.1006\/gyno.2003.6882_RF26","first-page":"815a","article-title":"Phase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with responsive low-burden advanced ovarian cancer (AOC): preliminary results of a GINECO\/FNCLCC\/SPGM-TC study","author":"Cur\u00e9","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1006\/gyno.2003.6882_RF27","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1200\/JCO.2001.19.4.1183","article-title":"Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy","volume":"19","author":"Schilder","year":"2001","journal-title":"J Clin Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082580396882X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082580396882X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,30]],"date-time":"2019-03-30T20:21:16Z","timestamp":1553977276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082580396882X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,1]]}},"alternative-id":["S009082580396882X"],"URL":"https:\/\/doi.org\/10.1006\/gyno.2003.6882","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2003,1]]}}}